| II-01 Khaled Abduljalil Simcyp Simulator within the DDMoRe Interoperability Framework – Proof of Concept Cases Wednesday 15:10-16:30 |
| II-02 João Abrantes Population pharmacokinetic analysis of factor VIII activity following treatment with moroctocog alfa in moderate to severe haemophilia A subjects Wednesday 15:10-16:30 |
| II-03 Malidi Ahamadi Population exposure –response analysis of “On-Off” time in Individuals with Parkinson Disease following Preladenant Treatment Wednesday 15:10-16:30 |
| II-04 Maurice Ahsman Modelling and simulation of oral GnRH Antagonist TAK-385 and testosterone-lowering response in Prostate Cancer Patients to Optimize Trial Design and Dose Selection Wednesday 15:10-16:30 |
| II-05 Sihem Bihorel A plateform PK/PD Model for Antibody Drug Conjugates Induced Myelosuppression Wednesday 15:10-16:30 |
| II-06 Ali Mohamed Ali Population pharmacokinetics of the amodiaquine: pooling data across different studies to optimize dosing in neglected populations Wednesday 15:10-16:30 |
| II-07 Hesham Al-Sallami Redefining normal variability of drug disposition Wednesday 15:10-16:30 |
| II-08 Silvana Alvariza Autoinduction of phenytoin hepatobiliary secretion as a mechanism for its nonlinear pharmacokinetics Wednesday 15:10-16:30 |
| II-09 Claire Ambery Balancing efficacy and risk: A case study of Phase 2 dose selection for an anti-inflammatory drug Wednesday 15:10-16:30 |
| II-10 Yasunori Aoki Model Averaging and Selection methods for model structure and parameter uncertainty quantification Wednesday 15:10-16:30 |
| II-11 Manel Aouri Population pharmacokinetics analysis of dolutegravir in HIV-1 infected individuals Wednesday 15:10-16:30 |
| II-12 Hyun-moon Back Development of QT prolongation model in guinea pig with hERG assay-in vivo PK- in-vivo QT effect to guide decision making in early drug discovery Wednesday 15:10-16:30 |
| II-13 Suruchi Bakshi Explaining the unexpected multi-stationarity in a nonlinear model of prolactin response to dopamine D2 receptor antagonists Wednesday 15:10-16:30 |
| II-14 Violeta Balbas-Martinez Target evaluation for Inflammatory Bowel Disease (IBD) using a Systems Pharmacology model Wednesday 15:10-16:30 |
| II-15 Kathryn Ball Prediction of food effect in the Chinese population using a PBPK model developed in a Caucasian population Wednesday 15:10-16:30 |
| II-16 Catalina Barceló Population pharmacokinetics analysis of elvitegravir and cobicistat in HIV-1 infected individuals Wednesday 15:10-16:30 |
| II-17 Charlotte Barker Simultaneous modelling of antimicrobial pharmacokinetic data from birth to adolescence: using different penicillins to inform a common maturation function Wednesday 15:10-16:30 |
| II-18 Ana Bastos Using modeling and simulation to design and evaluate dosing strategies for temocillin in haemodialysis patients Wednesday 15:10-16:30 |
| II-19 Levy Batista Mixed-effects ARX model identification of dynamical systems Wednesday 15:10-16:30 |
| II-20 Brendan Bender An integrated pharmacokinetic-pharmacodynamic modeling analysis of T-DM1–induced thrombocytopenia and hepatotoxicity in patients with HER2-positive metastatic breast cancer Wednesday 15:10-16:30 |
| II-21 Andrzej Bienczak Semi-physiological pharmacokinetic/pharmacogenetic model with circadian rhythm for the characterisation of nevirapine pharmacokinetics in African children. Wednesday 15:10-16:30 |
| II-22 Roberto Bizzotto Mixed-effect deconvolution: a new method applied to oral paracetamol absorption Wednesday 15:10-16:30 |
| II-23 Henrik Bjugård Nyberg Dismounting Saddles on the Likelihood Surface Wednesday 15:10-16:30 |
| II-24 Dimitra Bon PK-PD-VK modeling for hepatitis C treatment with the CI and Generalized multiscale model. Wednesday 15:10-16:30 |
| II-25 Charlotte Bon A target mediated cellular uptake model to assess the asialogycoprotein receptor shuttle capacity in hepatocytes Wednesday 15:10-16:30 |
| II-26 Irina Bondareva External validation and predictability of nonlinear models for changes in steady–state pharmacokinetics (PK) of carbamazepine (CBZ) and valproate (VPA) due to antiepileptic drug-drug interactions using sparse therapeutic drug monitoring (TDM) data Wednesday 15:10-16:30 |
| II-27 Jennifer Bonner Building of virtual geriatric cancer populations for physiologically-based pharmacokinetic modelling and simulation in cancer patients greater than 70 years of age Wednesday 15:10-16:30 |
| II-28 Elisa Borella Development and integration of the WinBUGS connector in the DDMoRe Interoperability Framework Wednesday 15:10-16:30 |
| II-29 Agnieszka Borsuk-De Moor Population pharmacokinetics of sufentanil after epidural and intravenous administration in children and infants Wednesday 15:10-16:30 |
| II-30 Margreke Brill Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis Wednesday 15:10-16:30 |
| II-31 Hannah Britz Physiologically-Based Pharmacokinetic (PBPK) Modeling of the Dronedarone Drug-Drug Interaction with Digoxin Wednesday 15:10-16:30 |
| II-32 Jantine Brussee Predictive performance of a CRP and organ failure based pharmacokinetic model for midazolam in critically ill children across external datasets in neonates, children and adults Wednesday 15:10-16:30 |
| II-33 Vincent Buchheit Added value of the Data Scientist role in a Clinical Pharmacometric group Wednesday 15:10-16:30 |
| II-34 Charles Burdet Joint modeling of plasma and fecal moxifloxacin pharmacokinetics in healthy volunteers Wednesday 15:10-16:30 |
| II-35 Elisa Calvier Allometric scaling of clearance in paediatrics: when does the magic of 0.75 fade? Wednesday 15:10-16:30 |
| II-36 Tim Cardilin Extending the Tumor Static Concentration curve to average doses – a combination therapy example using radiation therapy Wednesday 15:10-16:30 |
| II-37 Luzelena Caro Population Pharmacokinetics Modeling Characterizes the Higher Grazoprevir Exposure in Japanese Compared to Non-Japanese HCV-Infected Patients Wednesday 15:10-16:30 |
| II-38 Letizia Carrara Methods and tools for multiscale modelling in Systems Pharmacology: a review Wednesday 15:10-16:30 |
| II-39 Jason Cawley Competitive brain and body growth model Wednesday 15:10-16:30 |
| II-40 Pascal Chanu A model to predict progression free survival in patients with previously untreated HER2-positive progressive or recurrent locally advanced or metastatic breast cancer based on tumor growth inhibition metrics Wednesday 15:10-16:30 |
| II-41 Aziz Chaouch Building up a posteriori percentiles for Therapeutic Drug Concentration Monitoring Wednesday 15:10-16:30 |
| II-42 Jonathan Chard Pharmacometrics workflow: standards for provenance capture and workflow definition Wednesday 15:10-16:30 |
| II-43 Christophe Chassagnole Modelling the Emergence of Resistance to Chemotherapeutics with Virtual Tumour Wednesday 15:10-16:30 |
| II-44 Chunli Chen Assessment of Pharmacodynamic Interactions in the Mycobacteria Tuberculosis Infected Mouse using The Multistate Tuberculosis Pharmacometric Model and the General Pharmacodynamic Interaction Model Wednesday 15:10-16:30 |
| II-45 Charles Chen Comparison of Recursive Partitioning Analysis and Receiver Operating Characteristic (ROC) Analysis for Patient Identification Wednesday 15:10-16:30 |
| II-46 Maxwell Chirehwa Semi-mechanistic pharmacokinetic model for Isoniazid and Acetyl isoniazid in a cohort of TB/HIV co-infected patients Wednesday 15:10-16:30 |
| II-47 Hyewon Chung Population pharmacokinetics of F-ara-A after fludarabine administration in pediatric hematopoietic stem cell transplantation patients Wednesday 15:10-16:30 |
| II-48 Laurent Claret A model to predict progression-free survival in patients with renal cell carcinoma based on week 8 change in tumor size Wednesday 15:10-16:30 |
| II-49 Yumi Cleary Physiologically –based pharmacokinetic (PBPK) and population PK (PPK) modeling for basimglurant - assessment of predicted variability by the PBPK model and its utility Wednesday 15:10-16:30 |
| II-50 Oskar Clewe Pre-clinical Susceptibility Characterization and Pharmacodynamic Interaction Assessment Using the Multistate Tuberculosis Pharmacometric Model Wednesday 15:10-16:30 |
| II-51 Pieter Colin Propofol breath monitoring as a potential tool to improve the prediction of intraoperative plasma concentrations Wednesday 15:10-16:30 |
| II-52 Emmanuelle Comets Operational characteristics of saemix, an R package implementing the SAEM algorithm Wednesday 15:10-16:30 |
| II-53 Valerie Cosson Amyloid related imaging abnormalities (ARIA): Time to event modeling to identify new Phase 3 doses and dosing regimens for Gantenerumab Wednesday 15:10-16:30 |
| II-54 Sinziana Cristea Maturation of Glomerular Filtration throughout the paediatric age-range; a comparison of different functions Wednesday 15:10-16:30 |
| II-55 Damien Cronier PK/PD Modeling of Overall and Progression-Free Survival in Advanced Soft Tissue Sarcoma Patients Treated With Olaratumab in Combination with Doxorubicin. Wednesday 15:10-16:30 |
| II-56 Salvatore D'Agate Optimisation of weight-banded dosing regimens of amoxicillin in neonates and young infants with sepsis Wednesday 15:10-16:30 |
| II-57 André Dallmann Validation of a Population Physiologically-Based Pharmacokinetic Model for Pregnant Women Wednesday 15:10-16:30 |
| II-58 Fabrizia D'Antonio Effect of psychotic subtypes on cognitive trajectories in Alzheimer’s disease Neuroimaging Initiative ADNI2. Wednesday 15:10-16:30 |
| II-59 Pieter De Cock piperacillin-tazobactam pharmacokinetics in critically ill children: implications on adequate dosing regimens Wednesday 15:10-16:30 |
| II-60 Miné De Kock Pharmacokinetics of Sulfadoxine and Pyrimethamine for intermittent preventive treatment of malaria during Pregnancy and after delivery. Wednesday 15:10-16:30 |
| II-61 Bernardo de Miguel Lillo Modeling the dynamics of alanine aminotransferase in advanced cancer patients treated with kahalalide F Wednesday 15:10-16:30 |
| II-62 Mailys De Sousa Mendes A physiologically based pharmacokinetic model for a drug metabolized by several CYP450 during pregnancy Wednesday 15:10-16:30 |
| II-63 Aurelia de Vries Schultink Pharmacokinetics of MCLA-128 in cynomolgus monkeys and extrapolation to humans to support selection of first-in-human dose Wednesday 15:10-16:30 |
| II-64 Brenda de Winter Pharmacokinetics of Pentobarbital in Pediatric Status Epilepticus Patients Wednesday 15:10-16:30 |
| II-65 Wilbert de Witte High drug-target association rates increase the duration of in vivo target occupancy Wednesday 15:10-16:30 |
| II-66 Amelia Deitchman Tetracycline against Pseudomonas aeruginosa: Pharmacokinetic/Pharmacodynamic Modeling of In Vitro Time-Kill Curves Wednesday 15:10-16:30 |
| II-67 Laurence Del Frari Predicting human pharmacokinetics of monoclonal antibodies by allometric translation from preclinical data: a case study Wednesday 15:10-16:30 |
| II-68 Ivan Demin Guidance on dose-finding studies for biostatisticians and pharmacometricians: a Pharmacometrics perspective Wednesday 15:10-16:30 |
| II-69 Paolo Denti Population Pharmacokinetics of Levofloxacin in South African children. Wednesday 15:10-16:30 |
| II-70 Christiane Dings Pharmacokinetic and Pharmacodynamic Modeling of Acetylsalicylic Acid and its Major Metabolite Salicylic Acid Wednesday 15:10-16:30 |
| II-72 Thomas Dorlo Translational PKPD modeling framework to assess the predictive performance of a preclinical visceral leishmaniasis hamster model Wednesday 15:10-16:30 |
| II-73 Anne-Gaelle Dosne Robust QT prolongation assessment using model-averaging Wednesday 15:10-16:30 |
| II-74 Erwin Dreesen Anti-drug antibodies, low serum albumin and high C-reactive protein increase infliximab clearance in patients with inflammatory bowel disease: a population pharmacokinetic study of the TAXIT trial Wednesday 15:10-16:30 |
| II-75 Stefanie Drescher An Integrated Model for Glucose and Insulin Regulation in Bariatric Surgery Patients following Intravenous Glucose Tolerance Test Wednesday 15:10-16:30 |
| II-76 Hélder Duarte Amikacin in premature newborn: a new therapeutic proposal from a PopPK model Wednesday 15:10-16:30 |
| II-77 Vincent Dubois Joint modelling of pain intensity and informative dropout in moderate to severe chronic pain patients Wednesday 15:10-16:30 |
